<code id='92026385D9'></code><style id='92026385D9'></style>
    • <acronym id='92026385D9'></acronym>
      <center id='92026385D9'><center id='92026385D9'><tfoot id='92026385D9'></tfoot></center><abbr id='92026385D9'><dir id='92026385D9'><tfoot id='92026385D9'></tfoot><noframes id='92026385D9'>

    • <optgroup id='92026385D9'><strike id='92026385D9'><sup id='92026385D9'></sup></strike><code id='92026385D9'></code></optgroup>
        1. <b id='92026385D9'><label id='92026385D9'><select id='92026385D9'><dt id='92026385D9'><span id='92026385D9'></span></dt></select></label></b><u id='92026385D9'></u>
          <i id='92026385D9'><strike id='92026385D9'><tt id='92026385D9'><pre id='92026385D9'></pre></tt></strike></i>

          fashion

          fashion

          author:comprehensive    Page View:1
          Glaxo Smith Kline
          Akira Suemori/AP

          A few years ago, Vijay Pande, then a professor at Stanford who was using computer science to understand biology, was deciding whether to leave full-time academic work to become a venture capitalist. He turned to Andrew Ng, another Stanford professor who had joined Google Brain and later the Chinese search firm Baidu.

          “The things that we dreamed about five or 10 years ago were happening now,” Pande recalled Ng telling him. “The question was, do you want to be a part of it? Or do you want to write another paper?”

          advertisement

          Pande decided to become a venture capitalist. The result, he told an audience at a STAT event in San Francisco last week, is that, whereas he managed about $1 million to $2 million in research as a top academic, he now works at the fabled Silicon Valley firm Andreessen Horowitz, which invests $100 million a year.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          Prior authorization will have to move faster under new Biden rule
          Prior authorization will have to move faster under new Biden rule

          AdobeTheBidenadministrationmovedWednesdaytoforceinsurancecompaniestogivespecificreasonsfordenyingcov

          read more
          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more

          The response to Covid

          AdobeInMarch,ateamofChinesescientistsstudyingwhethertheantiviralremdesivirwaseffectiveagainstCovid-1